Sun Pharma receives tentative approval for Amifostine

RELATED NEWS Sun Pharma Q2 net profit up at Rs 186.4cr Sun Pharma Q1 cons net seen up 5% at Rs 150cr ALSO READ See latest News about Sun Pharma See previous management interviews See what other Experts & Brokerages are saying about Sun Pharma Sun Pharma BSE | NSE 10/02/12 Are Mutual Funds betting on Sun Pharma?

Sun Pharma today announced that it had received tentative approval from the USFDA for Amifostine for injection 500mg, filed from its site in India.

 

Amifostine is used as an adjuvant in cancer treatment. Sun Pharma's amifostine injection will be indicated for the reduction of kidney damage in patients who have advanced ovarian cancer and are being given repeat doses of cisplatin.

 

Ethyol is currently covered under 3 patents-'471 (July 31,2012), '731 (July 31,2012) and '409 (Dec 8,2017). Sun Pharma filed an ANDA with para IV certification against all the patents. Medimmune filed a suit against Sun Pharma in the District Court of Maryland. Sun Pharma has filed a motion for summary judgment for non-infringement.

 

Sun Pharma markets this product in India based on the formulation developed at its R&D center, SPARC. Sun Pharma is completely integrated for this product and manufactures the API at its plant in Ahmednagar.

 

 

Sourced From: Sun Pharmaceutical Industries Ltd